Literature DB >> 26656692

Predicting Disease Severity and Viral Spread of H5N1 Influenza Virus in Ferrets in the Context of Natural Exposure Routes.

Kathryn M Edenborough1, Suzanne Lowther2, Karen Laurie3, Manabu Yamada2, Fenella Long2, John Bingham2, Jean Payne2, Jennifer Harper2, Jessica Haining2, Rachel Arkinstall2, Brad Gilbertson1, Deborah Middleton2, Lorena E Brown4.   

Abstract

UNLABELLED: Although avian H5N1 influenza virus has yet to develop the capacity for human-to-human spread, the severity of the rare cases of human infection has warranted intensive follow-up of potentially exposed individuals that may require antiviral prophylaxis. For countries where antiviral drugs are limited, the World Health Organization (WHO) has developed a risk categorization for different levels of exposure to environmental, poultry, or human sources of infection. While these take into account the infection source, they do not account for the likely mode of virus entry that the individual may have experienced from that source and how this could affect the disease outcome. Knowledge of the kinetics and spread of virus after natural routes of exposure may further inform the risk of infection, as well as the likely disease severity. Using the ferret model of H5N1 infection, we compared the commonly used but artificial inoculation method that saturates the total respiratory tract (TRT) with virus to upper respiratory tract (URT) and oral routes of delivery, those likely to be encountered by humans in nature. We show that there was no statistically significant difference in survival rate with the different routes of infection, but the disease characteristics were somewhat different. Following URT infection, viral spread to systemic organs was comparatively delayed and more focal than after TRT infection. By both routes, severe disease was associated with early viremia and central nervous system infection. After oral exposure to the virus, mild infections were common suggesting consumption of virus-contaminated liquids may be associated with seroconversion in the absence of severe disease. IMPORTANCE: Risks for human H5N1 infection include direct contact with infected birds and frequenting contaminated environments. We used H5N1 ferret infection models to show that breathing in the virus was more likely to produce clinical infection than swallowing contaminated liquid. We also showed that virus could spread from the respiratory tract to the brain, which was associated with end-stage disease, and very early viremia provided a marker for this. With upper respiratory tract exposure, infection of the brain was common but hard to detect, suggesting that human neurological infections might be typically undetected at autopsy. However, viral spread to systemic sites was slower after exposure to virus by this route than when virus was additionally delivered to the lungs, providing a better therapeutic window. In addition to exposure history, early parameters of infection, such as viremia, could help prioritize antiviral treatments for patients most at risk of succumbing to infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26656692      PMCID: PMC4733973          DOI: 10.1128/JVI.01878-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  The first case of H5N1 avian influenza infection in a human with complications of adult respiratory distress syndrome and Reye's syndrome.

Authors:  A S Ku; L T Chan
Journal:  J Paediatr Child Health       Date:  1999-04       Impact factor: 1.954

2.  Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.

Authors:  K Y Yuen; P K Chan; M Peiris; D N Tsang; T L Que; K F Shortridge; P T Cheung; W K To; E T Ho; R Sung; A F Cheng
Journal:  Lancet       Date:  1998-02-14       Impact factor: 79.321

3.  Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997.

Authors:  A W Mounts; H Kwong; H S Izurieta; Y Ho; T Au; M Lee; C Buxton Bridges; S W Williams; K H Mak; J M Katz; W W Thompson; N J Cox; K Fukuda
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Severity of clinical disease and pathology in ferrets experimentally infected with influenza viruses is influenced by inoculum volume.

Authors:  Ian N Moore; Elaine W Lamirande; Myeisha Paskel; Danielle Donahue; Heather Kenney; Jing Qin; Kanta Subbarao
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

5.  Nasal pH measurement: a reliable and repeatable parameter.

Authors:  R J England; J J Homer; L C Knight; S R Ell
Journal:  Clin Otolaryngol Allied Sci       Date:  1999-02

6.  Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.

Authors:  Elena A Govorkova; Jerold E Rehg; Scott Krauss; Hui-Ling Yen; Yi Guan; Malik Peiris; Tien D Nguyen; Thi H Hanh; Pilipan Puthavathana; Hoang T Long; Chantanee Buranathai; Wilina Lim; Robert G Webster; Erich Hoffmann
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

7.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness.

Authors:  K Subbarao; A Klimov; J Katz; H Regnery; W Lim; H Hall; M Perdue; D Swayne; C Bender; J Huang; M Hemphill; T Rowe; M Shaw; X Xu; K Fukuda; N Cox
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

8.  Pathogenesis of avian influenza A (H5N1) viruses in ferrets.

Authors:  Lois A Zitzow; Thomas Rowe; Timothy Morken; Wun-Ju Shieh; Sherif Zaki; Jacqueline M Katz
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  Pathology of fatal human infection associated with avian influenza A H5N1 virus.

Authors:  K F To; P K Chan; K F Chan; W K Lee; W Y Lam; K F Wong; N L Tang; D N Tsang; R Y Sung; T A Buckley; J S Tam; A F Cheng
Journal:  J Med Virol       Date:  2001-03       Impact factor: 2.327

10.  Characterization of H5N1 influenza virus variants with hemagglutinin mutations isolated from patients.

Authors:  Yohei Watanabe; Yasuha Arai; Tomo Daidoji; Norihito Kawashita; Madiha S Ibrahim; Emad El-Din M El-Gendy; Hiroaki Hiramatsu; Ritsuko Kubota-Koketsu; Tatsuya Takagi; Takeomi Murata; Kazuo Takahashi; Yoshinobu Okuno; Takaaki Nakaya; Yasuo Suzuki; Kazuyoshi Ikuta
Journal:  MBio       Date:  2015-04-07       Impact factor: 7.867

View more
  5 in total

1.  1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarespiratory Tissues of Ferrets.

Authors:  Emmie de Wit; Jurre Y Siegers; Jacqueline M Cronin; Sarah Weatherman; Judith M van den Brand; Lonneke M Leijten; Peter van Run; Lineke Begeman; Henk-Jan van den Ham; Arno C Andeweg; Trenton Bushmaker; Dana P Scott; Greg Saturday; Vincent J Munster; Heinz Feldmann; Debby van Riel
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

2.  Intranasal administration of inactivated avian influenza virus of H5N1 subtype vaccine-induced systemic immune response in chicken and mice.

Authors:  I N Suartha; G A A Suartini; I W Wirata; N M A R K Dewi; G N N Putra; G A Y Kencana; G N Mahardika
Journal:  Vet World       Date:  2018-02-20

Review 3.  The Drivers of Pathology in Zoonotic Avian Influenza: The Interplay Between Host and Pathogen.

Authors:  William S J Horman; Thi H O Nguyen; Katherine Kedzierska; Andrew G D Bean; Daniel S Layton
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

4.  The Dynamics of the Ferret Immune Response During H7N9 Influenza Virus Infection.

Authors:  William S J Horman; Thi H O Nguyen; Katherine Kedzierska; Jeffrey Butler; Songhua Shan; Rachel Layton; John Bingham; Jean Payne; Andrew G D Bean; Daniel S Layton
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

Review 5.  In Vivo Models to Study the Pathogenesis of Extra-Respiratory Complications of Influenza A Virus Infection.

Authors:  Edwin Veldhuis Kroeze; Lisa Bauer; Valentina Caliendo; Debby van Riel
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.